semaj83/ctmatch_classification huggingface dataset:
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Histologically confirmed diffuse or mediastinal large B-cell lymphoma*, meeting the following Advanced or metastatic disease, Incurable by standard therapies, Relapsed or refractory disease [Note: *Patients with diffuse large B-cell lymphoma whose disease has transformed from an earlier diagnosis of low grade lymphoma (i.e., an indolent histology) are eligible] Bidimensionally measurable disease** by CT scan, MRI, or physical exam, with >= 1 disease site meeting 1 of the following Lymph nodes >= 1.5 cm x 1.5 cm by spiral CT scan, Non-nodal regions >= 1 cm x 1 cm by MRI, CT scan, or physical exam [Note: **Bone lesions are not considered bidimensionally measurable disease] Received 1-2 prior chemotherapy regimens that included doxorubicin hydrochloride; Prior stem cell transplantation and high-dose chemotherapy is considered one regimen; One prior non-chemotherapy regimen in the form of radiation allowed; Measurable disease must be outside the previously irradiated area No sole site of disease in a previously irradiated area unless progressive disease or new lesions are documented; Low-dose palliative radiotherapy may be allowed No known brain metastases Life expectancy >= 12 weeks ECOG performance status 0-1 Absolute granulocyte count >= 1,500/mm^3 Platelet count >= 100,000/mm^3 AST and ALT =< 2.5 times upper limit of normal (ULN)
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 13.0-25.0,  Schizophrenia Prodrome /written informed consent (for individuals under 18 written informed consent of at least one of the parents is required), 2. /age between 13 and 25 years, 3. /ARMS as classified by the PACE (Yung et al., 1998) PACE for ARMS one or more of following characteristics which must have occurred within the last 12 months Frank psychotic symptoms < 1 week (Transient psychosis group) Attenuated psychotic symptoms > 1 week, > 2 times per week Decline in global function (drop in GAF of > 30%) plus family history of psychosis or individual has schizotypal personality disorder To operationalize PACE duration and severity ratings of psychotic symptoms will be performed using the Positive and Negative Syndromes of Schizophrenia Scale (PANSS) (Kay et al., 1987) applying following cut-off scores, following Morrison et al (2002): Ad 1) Transient psychosis is defined with the presence of symptoms that score 4 or more on hallucinations, 4 or more on delusions, or 5 or more on conceptual disorganizations, last less than one week and resolve without antipsychotic medication. Ad 2) Attenuated psychotic symptoms are defined by the presence of symptoms that score 3 on delusions, 2-3 on hallucinations, 3-4 on suspiciousness or 3-4 on conceptual disorganization  /Acute suicidal behaviour, aggressive behaviour (PANSS hostility, suicidality = 7), 2. /Drug abuse that contributed decisively to the presentation of the index episode, (dependency on morphine, cocaine, amphetamine, but not THC), 3. /Alcohol abuse if considered as major problem, 4. /Epilepsy, 5. /Mental Retardation (IQ<80), 6. /Pregnancy and lactation, 7. /Structural changes in MRI or CT scan (e.g., tumours), expect for enlargement of ventricles or sulci, 8. /Previous history of antipsychotic drug (>1 week) or mood stabilizer treatment, 9. /Laboratory values more than 10% outside the normal range for transaminases, CRP or bleeding parameters, 10. /Individuals with organic brain syndrome, 11. /Individuals who are taking anticoagulants, 12. /Individuals who are taking omega 3 supplements, currently or within 8 weeks of being included in the trial, 13. /Individuals who have other, severe, intercurrent illness which in the opinion of the investigator may put them at risk or influence the results of the trial or affect ability to take part in the trial
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Enterobacteriaceae Infections Bacteremia Pneumonia Skin Diseases Urinary Tract Infections All patients with infections (i.e. bacteremia, pneumonia, abdomen infections, skin infections, and urinary tract infections) caused by ESBL-producing Enterobacteriaceae  Children < 16 years
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Lymphoma, Non-Hodgkin Lymphoma, B-Cell Small Lymphocytic Lymphoma Follicular Cell Lymphoma (grades I and II) Mantle Cell Lymphoma patients that are not considered eligible for high-dose therapy and stem cell transplant Lymphoplasmacytic lymphoma including Waldenstrom's Macroglobulinemia Marginal Zone Lymphoma MALT Lymphoma that has ONLY failed antibiotic therapy or involved field radiation Adequate bone marrow function, renal function, and hepatic function as outlined in details below ECOG performance status of 0, 1, or 2 Able to read, understand, and sign an IRB approved informed consent  Known HIV positive status Known CNS involvement Prior therapy for lymphoma antibiotic treatment for MALT-Type NHL
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 1.0-40.0,  Cholera Diarrhea Vibrio Infections Healthy adult male and non-pregnant female adults aged 18-40 years and healthy children aged 1-17 years All subjects must satisfy the following at study entry Male or female adult residents aged 18-40 years or children aged 1 years who the investigator believes will comply with the requirements of the protocol (i.e. available for follow-up visits and specimen collection) For females of reproductive age, they must not be pregnant (as determined by verbal screening) Written informed consent obtained from subjects or their guardians, and written assent for children aged 12-17 years Healthy subjects as determined by: medical history, physical examination, clinical judgement of the investigator  Ongoing serious chronic disease Immunocompromising condition or therapy Diarrhea (3 or more loose stools within a 24-hour period) 6 weeks prior to enrollment one or two episodes of diarrhea lasting for more than 2 weeks in the past 6 months one or two episodes of abdominal pain lasting for more than 2 weeks in the past 6 months intake of any anti-diarrhoeal medicine in the past week abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting in the past 24 hours acute disease one week prior to enrollment, with or without fever. Temperature > or = 38 degrees C (oral) or axillary temperature > or = 37.5 degrees C warrants deferral of the vaccination pending recovery of the subject receipt of antibiotics in past 14 days receipt of live or killed enteric vaccine in last month
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Restless Legs Syndrome Patients with a diagnosis of RLS Body mass index of 18 to 32 kg/m², with a body weight of at least 50 kg Normal blood pressure pre-study Light smokers only (<20/day)  History of postural hypotension or faints Secondary RLS Patients who suffer from a primary sleep disorder other than RLS Patients diagnosed with movement disorders Patients with unstable medical conditions Patients with personal or family history of adverse reactions or hypersensitivity to the study drug Patients with abnormal laboratory values Patients with hepatitis or HIV Patients who abuse alcohol or drugs Patients taking the following medications: dopamine agonists (including ropinirole), dopamine antagonists (e.g., metoclopramide and domperidone), levodopa/carbidopa
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 1.5-999.0,  Acute Diarrhea All patients having acute diarrhea i.e. 3 or more stools per day or stool weight exceeding 200 grams lasting less than 15 days  Patients having the following diagnosis as they might have high calprotectin levels not only because of the diarrhea per se but may also be because of the underlying pathology itself Inflammatory bowel disease (Crohn's disease, ulcerative disease) Gastrointestinal malignancy (colorectal cancer, gastric cancer etc) Cirrhosis of liver Chronic pancreatitis Currently on non steroidal anti inflammatory therapy Younger than 1 year of age
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Inflammatory Bowel Diseases Patient will be 10 years and older Patient suffers from abdominal pain and/or diarrhea for the last 6 weeks and/or expresses extra-intestinal manifestations of CD Patient has at least one of the following over the preceding 6 months (plus symptoms suspicious of small bowel Crohn's Disease) Positive inflammatory marker (ESR, CRP, thrombocytosis, leucocytosis, fecal lactoferrin, fecal α-1 antitrypsin) Unexplained anemia Recurrent fever Weight loss (at least 10% of normal body weight in adults) Hypoalbuminaemia (<3.5 g/dL) Gastro-intestinal bleeding Chronic perianal disease (fistula, fissure)  Patients with indeterminate colitis where the purpose is only to make a definitive diagnosis and where the are not otherwise met Patient is known to suffer from intestinal obstruction (symptoms such as severe abdominal pain with accompanying nausea or vomiting) Definite stricture seen on SBFT Patient had suspected GI stricture, a Given® Patency capsule was administered and Patient did not pass the Patency capsule Patient has a pacemaker or other implanted electro-medical device Patient has known history of small bowel Crohn's disease Patient on treatment for active IBD Patient with suspected celiac disease that has not been excluded Patient on non-steroidal anti-inflammatory drugs including Aspirin, (twice weekly or higher) during the 3 months preceding enrolment Patient is pregnant
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Diarrhea Male or female between 18 and 45 years of age General good health, without significant medical illness, abnormal physical examination findings or clinical laboratory abnormalities as determined by principal investigator Demonstrate comprehension of the protocol procedures and knowledge of ETEC illness by passing a written examination (pass grade ≥ 70%) Willing to participate after informed consent obtained Available for all planned follow-up visits Negative serum pregnancy test at screening and a negative urine pregnancy test on the day of admittance to the inpatient phase for female volunteers of childbearing potential. Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable. Female volunteers unable to bear children must have this documented (e.g., tubal ligation or hysterectomy)  Presence of a significant medical condition, (e.g. psychiatric conditions or gastrointestinal disease, such as peptic ulcer, symptoms or evidence of active gastritis or gastroesophageal reflux disease, inflammatory bowel disease, alcohol or illicit drug abuse/dependency), or other laboratory abnormalities which in the opinion of the investigator precludes participation in the study Immunosuppressive illness or IgA deficiency (below the normal limits) Positive serology results for HIV, HBsAg, or HCV antibodies Significant abnormalities in screening lab hematology, serum chemistry, urinalysis or EKG (EKG in volunteers ≥ 40 years), as determined by PI Allergy to fluoroquinolones, trimethoprim-sulfamethoxazole, or ampicillin/penicillin (excluded if allergic to two of three) Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day) on a regular basis History of diarrhea in the 2 weeks prior to planned inpatient phase Regular use of laxatives, antacids, or other agents to lower stomach acidity (regular defined as at least weekly) Use of antibiotics during the 7 days before dosing or proton pump inhibitors, H2 blockers, or antacids within 48 hours of dosing Travel to countries where ETEC or cholera infection is endemic (most of the developing world) within two years prior to dosing
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 0.154-0.385,  Diarrhea Access to telephone at home or in the immediate neighborhood. 2. Healthy male and female non-malnourished (weight for length not ≤ -3 SD of WHO child growth standards) infants aged 6 weeks (till 6 weeks + 2 days). 3. Parent's permission to participate in the study is available. 4. No plans to travel over the next 4 months  Gestational age <37 weeks. 2. Any major physical congenital malformation. 3. Living in a household or has contact with an individual who is immunosuppressed. 4. Hospitalized once or more for the following illnesses since birth: heart disease, pneumonia, sepsis, meningitis, unconsciousness. 5. Is required to take daily medications other than vitamins or herbal "tonics". 6. Evidence of cardiovascular disease as indicated by any of the following Central cyanosis Cyanotic or apnoeic spells Features of congestive heart failure Significant heart murmur detected on physical examination 7. Evidence of gastrointestinal disease indicated by following Diarrhea in the previous 7 days Blood in the stools any time since birth 8. Evidence of neurological disease, as indicated by History of seizures any time since birth History of unconsciousness Focal deficit on physical examination 9. Evidence of liver or other reticuloendothelial disease, as indicated by any of the following
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 15.0-75.0,  Crohn's Disease Subjects who successfully enrolled in and completed the M04-729, (NCT00445939) study  Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study
Patient description: A 17 year old boy complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows: Hemoglobin: 9.7 g/dL Platelet: 110,000 /cu.mm Creatinine: 3.6 mg/dL blood urea nitrogen (BUN): 73 mg/dL direct bilirubin: 2.4 mg/dL lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L) Peripheral blood smear showed a moderate number of schistocytes and helmet cells. Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. He has no other underlying disease and he is not on any medications.

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  Diabetes Mellitus Hypertension Men or women of any racial background Age >= 40 years and <= 75 years SBP>= 130 mmHg and < 140 mmHg or DBP >= 85 mmHg and < 90 mmHg, average of screening and randomisation visits (in absence of any antihypertensive medication) FG >=100 mg/dl (5.6 mmol/l) and < 126 mg/dl (7.0 mmol/l) between screening and randomisation (in absence of any antidiabetic medication) Waist circumference >= 102 cm in men and >= 88 cm in women  SBP >= 140 mmHg or DBP >= 90 mmHg Any antihypertensive, antidiabetic or antiobesity medication at the time of or during the 6 months previous to randomisation Any current or previous cardiovascular or renal disease requiring continuous administration of Ds, ßBs, ACEIs, ARBs, CAs, and any other antihypertensive medication Any medical condition preventing adherence to lifestyle measures included in the protocol Hepatic disease as AST (SGOT) or ALT (SGPT) values equal or greater than two times the upper limit of normal Chronic renal dysfunction as serum creatinine > 2.0 mg/dl Any gastrointestinal disorder interfering with drug absorption Known allergy or contraindications to ACEIs or ARBs Pregnant or lactating women; women in reproductive age not using recognized contraceptive methods Malignancy within the last 5 years